AIP
RXRX icon

Ameritas Investment Partners’s Recursion Pharmaceuticals RXRX Stock Holding History

Ameritas Investment Partners’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$115K Buy
37,513
+6,870
+22% +$26.5K ﹤0.01% 1607
2025
Q4 		$125K Hold
30,643
– – ﹤0.01% 1561
2025
Q3 		$150K Sell
30,643
-4,026
-12% -$21.1K ﹤0.01% 1433
2025
Q2 		$175K Buy
34,669
+8,639
+33% +$42.4K 0.01% 1381
2025
Q1 		$138K Hold
26,030
– – ﹤0.01% 1494
2024
Q4 		$176K Buy
26,030
+1,875
+8% +$12.6K 0.01% 1403
2024
Q3 		$159K Buy
24,155
+3,903
+19% +$28K 0.01% 1481
2024
Q2 		$152K Buy
20,252
+6,692
+49% +$58.4K 0.01% 1452
2024
Q1 		$135K Hold
13,560
– – ﹤0.01% 1544
2023
Q4 		$134K Hold
13,560
– – ﹤0.01% 1541
2023
Q3 		$104K Buy
13,560
+2,290
+20% +$22.8K ﹤0.01% 1630
2023
Q2 		$84.2K Buy
11,270
+1,129
+11% +$7.9K ﹤0.01% 1712
2023
Q1 		$67.6K Hold
10,141
– – ﹤0.01% 1790
2022
Q4 		$88.3K Hold
10,141
– – ﹤0.01% 1685
2022
Q3 		$107K Hold
10,141
– – ﹤0.01% 1439
2022
Q2 		$82K Buy
10,141
+1,233
+14% +$8.25K ﹤0.01% 1657
2022
Q1 		$64K Hold
8,908
– – ﹤0.01% 1918
2021
Q4 		$153K Buy
8,908
+6,751
+313% +$127K 0.01% 1411
2021
Q3 		$50K Buy
2,157
+500
+30% +$14.2K ﹤0.01% 2156
2021
Q2 		$60K Buy
+1,657
New +$49K ﹤0.01% 2068

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ameritas Investment Partners's RXRX Position: Q1 2026 in Review

Ameritas Investment Partners increased its Recursion Pharmaceuticals (RXRX) stake by 22% in Q1 2026, buying an estimated $26.5K and bringing the position to 37,513 shares worth $115K. The position accounts for ﹤0.01% of the portfolio, ranked #1607.

Ameritas Investment Partners first reported a position in RXRX in Q2 2021 and has held it in 20 quarters since. The position peaked at $176K in Q4 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Ameritas Investment Partners held 37,513 shares of Recursion Pharmaceuticals worth $115K as of Q1 2026.
  • Ameritas Investment Partners bought 6,870 Recursion Pharmaceuticals shares in Q1 2026, an estimated $26.5K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #1607 holding.
  • Ameritas Investment Partners first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • Ameritas Investment Partners's Recursion Pharmaceuticals position peaked at $176K in Q4 2024.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.